Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
NCT ID: NCT03199053
Last Updated: 2024-06-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
256 participants
INTERVENTIONAL
2017-10-11
2024-01-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
NCT01619059
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
NCT01204775
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
NCT02681094
A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
NCT02419612
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
NCT02284893
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose Dapagliflozin
Oral route. Start with a low dose of dapagliflozin administered once daily and remain on the low dose regardless of your HbA1c at week 12.
Dapagliflozin
Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
Low dose/high dose Dapagliflozin
Oral route. Start with a low dose of Dapagliflozin administered once daily and up titrate to the high dose Dapagliflozin administered once daily if HbA1c \>= 7% at week 12
Dapagliflozin
Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
Low dose Saxagliptin
Oral route. Start with a low dose of saxagliptin administered once daily and remain on the low dose regardless of your HbA1c at week 12
Saxagliptin
Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
Low dose/high dose Saxagliptin
Oral route. Start with a low dose of saxagliptin administered once daily and up titrate to the high dose if HbA1c \>= 7% at week 12
Saxagliptin
Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
Placebo arm
Oral route. Placebo tablets administered for 52 weeks
Placebo
Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dapagliflozin
Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
Saxagliptin
Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
Placebo
Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Target Population
* Previously diagnosed with Type 2 Diabetes Mellitus by World Health Organization/ADA criteria
* HbA1c between 6.5% and 10.5% obtained at screening.
* Currently on diet and exercise and stable dose of at least 1000 mg metformin (IR or XR) for a minimum of 8 weeks, or stable dose of insulin for a minimum of 8 weeks, or a stable combination of at least 1000 mg metformin (IR or XR) and insulin for a minimum of 8 weeks prior to randomization. For those children on insulin, investigators will confirm that attempts at removing insulin from the subject's therapeutic regimen had been previously made but had not been successful.
* Age and Reproductive Status
* Male and female patients eligible if 10 years of age, up to but not including 18 years of age at the time of enrollment/screening. At least 30% of total subjects will be between the ages of 10 and 14 years and at least one third, but no more than two thirds, female subjects.
* Women of childbearing potential must have a negative pregnancy test within 24 hours prior to the start of study drug.
* Women must not be breastfeeding.
* Women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drugs: saxagliptin, and dapagliflozin, plus 5 half-lives of study drugs or 30 days (whichever is longer), plus 30 days (duration of ovulatory cycle) for a total of 60 days post treatment completion.
Exclusion Criteria
* Presence of Type 1 diabetes, as demonstrated by Preexisting diagnosis of Type 1 diabetes,
* Previous diagnosis of monogenic etiology of Type 2 diabetes
* Diabetes ketoacidosis (DKA) within 6 months of screening
* Current use of the following medications for the treatment of diabetes, or use within the specified timeframe prior to screening for the main study:
* Eight weeks: sulfonylureas, alpha glucosidase inhibitors, metiglinide, oral or injectable incretins or incretin mimetics, other antidiabetes medications not otherwise specified.
* Sixteen weeks: thiazolidinediones, DPP-4 inhibitors (with no reported medication related AEs related to DPP-4 inhibitors), sodium glucose cotransporter-2 (SGLT-2) inhibitors (with no reported medication related AEs related to SGLT-2 inhibitors)
* Initiation or discontinuation of prescription or non-prescription weight loss drugs within 8 weeks of screening. Use of prescription or non-prescription weight loss drugs must be stable during the study.
* Medical History and Concurrent Diseases
* Pregnant, positive serum pregnancy test, planning to become pregnant during the clinical trials, or breastfeeding
* History of unstable or rapidly progressive renal disease
* History of unresolved vesico-ureteral reflux
* History of or current, acute or chronic pancreatitis
* History of hemoglobinopathy, with the exception of sickle cell trait or thalassemia minor; or chronic or recurrent hemolysis
* Malignancy within 5 years of the screening visit (with the exception of treated basal cell or treated squamous cell carcinoma)
* Replacement or chronic systemic corticosteroid therapy, defined as any dose of systemic corticosteroid taken for \> 4 weeks within 3 months prior to the Day 1 visit
* Physical and Laboratory Test Findings
* Abnormal renal function,
* An abnormal thyroid-stimulating hormone (TSH) value at enrollment will be further evaluated for free T4. Subjects with abnormal free T4 values will be excluded.
* Hematuria (confirmed by microscopy at screening) with no explanation as judged by the Investigator up to randomization.
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2× upper limit of normal (ULN), or clinically significant hepatic disease.
* Serum total bilirubin (TB) \> 2x ULN unless exclusively caused by Gilbert's syndrome
* Positive serologic evidence of current infectious liver disease including anti hepatitis A virus (HAV) (IgM), hepatitis B surface antigen (HBsAg), or anti hepatitis C virus (HCV). Patients who have isolated positive anti-hepatitis B surface antibodies may be included.
* Anemia of any etiology
* Volume-depleted subjects.
* Allergies and Adverse Drug Reaction
* Known allergy, sensitivity or contraindication to any study drug or its excipient/vehicle
* Subject is currently abusing alcohol or other drugs or has done so within the last 6 months prior to the screening visit.
* Prisoners or subjects who are involuntarily incarcerated. (Note: under certain specific circumstances a person who has been imprisoned may be included or permitted to continue as a subject. Strict conditions apply and Sponsor/designee approval is required.)
* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
* Psychiatric or cognitive disorder that will, in the opinion of investigators, limit the subject's ability to comply with the study medications and monitoring.
* Subjects who have contraindications to therapy as outlined in the saxagliptin and dapagliflozin Investigator Brochure or local package inserts.
* Participation and receiving IP in another clinical study during the prior 3 months
10 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Sacramento, California, United States
Research Site
New Haven, Connecticut, United States
Research Site
Hialeah, Florida, United States
Research Site
Hialeah, Florida, United States
Research Site
Hollywood, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Miami Springs, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Atlanta, Georgia, United States
Research Site
Idaho Falls, Idaho, United States
Research Site
Neptune City, New Jersey, United States
Research Site
Memphis, Tennessee, United States
Research Site
Memphis, Tennessee, United States
Research Site
Edinburg, Texas, United States
Research Site
Harlingen, Texas, United States
Research Site
McAllen, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Charlottesville, Virginia, United States
Research Site
Buenos Aires, , Argentina
Research Site
Buenos Aires, , Argentina
Research Site
CABA, , Argentina
Research Site
Ciudad de Buenos Aires, , Argentina
Research Site
San Miguel de Tucumán, , Argentina
Research Site
San Miguel de Tucumán, , Argentina
Research Site
Blacktown, , Australia
Research Site
Brasília, , Brazil
Research Site
Curitiba, , Brazil
Research Site
Fortaleza, , Brazil
Research Site
Fortaleza, , Brazil
Research Site
Passo Fundo, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Ribeirão Preto, , Brazil
Research Site
Santa Maria, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Montreal, Quebec, Canada
Research Site
Santiago, , Chile
Research Site
Armenia, , Colombia
Research Site
Barranquilla, , Colombia
Research Site
Tampere, , Finland
Research Site
Ahmedabad, , India
Research Site
Aurangabad, , India
Research Site
Bangalore, , India
Research Site
Bikaner, , India
Research Site
Chandigarh, , India
Research Site
Coimbatore, , India
Research Site
Hyderabad, , India
Research Site
Kolkata, , India
Research Site
Kozhikode, , India
Research Site
Nashik, , India
Research Site
Pune, , India
Research Site
Visakhapatnam, , India
Research Site
Haifa, , Israel
Research Site
Ancona, , Italy
Research Site
Napoli, , Italy
Research Site
Roma, , Italy
Research Site
George Town, , Malaysia
Research Site
Ipoh, , Malaysia
Research Site
Johor Bahru, , Malaysia
Research Site
Klang, , Malaysia
Research Site
Kota Kinabalu, , Malaysia
Research Site
Kuala Lumpur, , Malaysia
Research Site
Kuching, , Malaysia
Research Site
Malacca, , Malaysia
Research Site
Putrajaya, , Malaysia
Research Site
Seremban, , Malaysia
Research Site
Seri Manjung, , Malaysia
Research Site
Taiping, , Malaysia
Research Site
Boca del Rio, , Mexico
Research Site
Celaya, , Mexico
Research Site
Ciudad Madero, , Mexico
Research Site
Cuernavaca, , Mexico
Research Site
Cuernavaca, , Mexico
Research Site
Culiacán, , Mexico
Research Site
Durango, , Mexico
Research Site
Guadalajara, , Mexico
Research Site
Juriquilla, , Mexico
Research Site
Mérida, , Mexico
Research Site
México, , Mexico
Research Site
México, D.F., , Mexico
Research Site
Monterrey, , Mexico
Research Site
Monterrey, , Mexico
Research Site
San Juan del Río, , Mexico
Research Site
Veracruz, , Mexico
Research Site
Zapopan, , Mexico
Research Site
Grafton, , New Zealand
Research Site
Tauranga, , New Zealand
Research Site
Wellington, , New Zealand
Research Site
Quezon City, , Philippines
Research Site
Quezon City, , Philippines
Research Site
San Fernando City, , Philippines
Research Site
Warsaw, , Poland
Research Site
Izhevsk, , Russia
Research Site
Moscow, , Russia
Research Site
Ufa, , Russia
Research Site
Daejeon, , South Korea
Research Site
Incheon, , South Korea
Research Site
Wŏnju, , South Korea
Research Site
Tainan City, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Bangkok, , Thailand
Research Site
Hat Yai, , Thailand
Research Site
Aydin, , Turkey (Türkiye)
Research Site
Bursa, , Turkey (Türkiye)
Research Site
Eskişehir, , Turkey (Türkiye)
Research Site
Istanbul, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Kocaeli, , Turkey (Türkiye)
Research Site
Kurupelit, , Turkey (Türkiye)
Research Site
Manisa, , Turkey (Türkiye)
Research Site
Dnipro, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Vinnytsia, , Ukraine
Research Site
Birmingham, , United Kingdom
Research Site
London, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Middlesbrough, , United Kingdom
Research Site
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Shehadeh N, Barrett T, Galassetti P, Karlsson C, Monyak J, Iqbal N, Tamborlane WV. Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes. NEJM Evid. 2023 Dec;2(12):EVIDoa2300210. doi: 10.1056/EVIDoa2300210. Epub 2023 Oct 4.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-005042-66
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D1680C00019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.